Last checked at 
Braveheart Investment Group PLC - investor in small- and medium-sized businesses based in Barnsley, England - Investee Paraytec looks to confirm "five-fold improvement" to its CX300 instrument, which tests for bacteraemia, which causes sepsis.
"Paraytec has designed a short prospective clinical study to evaluate the performance of the CX300, when measured not only against both PCR and lateral flow tests, but also by determining patient sample viral infectivity by culture on mammalian epithelial cells. This trial, which will monitor positive patients daily for up to 10 days, will enable the Paraytec team to establish the performance of the device in determining the presence of infectious virus, and is expected to start before the end of February," company explains.
Current stock price: 23.00 pence, up 4.6% on Friday
12-month change: down 47%
By Paul McGowan; paulmcgowan@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.